Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:58:47.704Z.
Calculation as of: 2026-10-06T19:58:47.704Z.
Quote observation: 2026-10-06T19:55:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 87d00981f6afc2d6fb42b8babadf75d30967326f42a5e12d4c63051d6ceded83
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$136.89M
EV/EBIT Ratio
N/A
TTM Avg
68.74x
3Y Avg
68.74x
5Y Avg
68.74x
Market Cap
$138.03M
EV/EBIT Ratio
N/A
TTM Avg
734.52x
3Y Avg
360.78x
5Y Avg
245.93x
Market Cap
$131.21M
EV/EBIT Ratio
N/A
TTM Avg
60.31x
3Y Avg
490.71x
5Y Avg
419.04x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | $135.73M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.89M | N/A | 68.74x | 68.74x | 68.74x |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.03M | N/A | 734.52x | 360.78x | 245.93x |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $138.49M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.50M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $131.30M | N/A | 204.78x | 204.78x | 204.78x |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | N/A | 60.31x | 490.71x | 419.04x |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
